Home / Companies / Iovance Biotherapeutics, Inc. / 10 Jun 2026
Iovance Biotherapeutics, Inc.: meeting of 10 Jun 2026
Votes reported on Form N-PX, item by item
318 Form N-PX filers reported votes at the Iovance Biotherapeutics, Inc. meeting of 10 Jun 2026. Their records fall into 7 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
6 nominees; 93.9% of reported votes for; 10 filers withheld from or voted against at least one nominee.
1,056 vote records from 89 filers. 1 of the 86 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
457 vote records from 316 filers. 117 of the 291 filers that marked the item either way voted against management. 25 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 264 filers; three years: 10 filers; for: 6 filers; not applicable: 2 filers; against: 2 filers; 1-year: 2 filers.
455 vote records from 311 filers. 13 of the 283 filers that marked the item either way voted against management. 28 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
176 vote records from 89 filers. 0 of the 86 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
187 vote records from 89 filers. 0 of the 86 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
171 vote records from 85 filers. 0 of the 82 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
175 vote records from 88 filers. 10 of the 85 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| Vanguard | For | For | Split or no vote | For |
| BlackRock and iShares | For | For | Split or no vote | For |
| Fidelity | For | For | Split or no vote | For |
| Dimensional | For | Against * | Split or no vote * | For |
| State Street and SPDR | For | For | Split or no vote | For |
| American Century | For | Against * | Split or no vote | For |
| Invesco | For | Against * | Split or no vote | For |
| Equitable | For | For | Split or no vote | For |
| Charles Schwab | For | For | Split or no vote | For |
| Nuveen and TIAA | For | For | Split or no vote | For |
| ProShares and ProFunds | For | Against * | Split or no vote | For |
| John Hancock and Manulife | For | Against * | Split or no vote | For |
| Morgan Stanley, Eaton Vance and Calvert | For | Against * | Split or no vote | For |
| J.P. Morgan | For | For | Split or no vote | For |
| Goldman Sachs | For | For | Split or no vote | For |
| WisdomTree | For | Against * | Split or no vote | For |
| PGIM and Prudential | For | For | Split or no vote | For |
| Jackson National funds | For | Against * | Split or no vote * | For |
| Northern Trust and FlexShares | For | For | Split or no vote | For |
| SEI | For | For | Split or no vote | For |
| T. Rowe Price | For | Against * | Split or no vote | For |
| Lincoln Financial | For | For | Split or no vote | For |
| Voya | For | Against * | Split or no vote | For |
| First Trust | No report | For | Split or no vote | No report |
| Russell Investments | For | For | Split or no vote | For |
| Nationwide | For | For | Split or no vote | For |
| Victory Capital | For | Against * | Split or no vote | For |
| Brighthouse Funds | For | For | For | For |
| Guggenheim and Rydex | For | Against * | Split or no vote | For |
| Columbia Threadneedle | For | Against * | Split or no vote | For |
| BNY Mellon | No report | Against * | Split or no vote | No report |
| Principal | For | Against * | Split or no vote | For |
| Pacific Life funds | For | For | Split or no vote | For |
| Global X | For | For | Split or no vote | For |
| Federated Hermes | For | For | Split or no vote | For |
| AllianceBernstein | No report | Against * | Split or no vote | No report |
| DWS | For | Against * | Split or no vote | For |
| Allspring | No report | Split or no vote | Split or no vote | No report |
| Neuberger Berman | No report | For | Split or no vote | No report |
| Baird | No report | Against * | Split or no vote | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Iovance Biotherapeutics, Inc. meeting?
318 Form N-PX filers reported votes at the meeting of 10 Jun 2026. On say-on-pay, 117 of 291 voted against management (40.2%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Iovance Biotherapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Iovance Biotherapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Iovance Biotherapeutics, Inc. with a meeting date within three days of 10 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.